About Aurobindo Pharma Limited (AUROPHARMA)
Aurobindo Pharma Limited is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in Hyderabad, India. AUROPHARMA has been publicly traded since 1996, giving it 30+ years of trading history.
Aurobindo Pharma Limited (AUROPHARMA) has been publicly traded since 1996, making it a 30-year-old public company. It operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company is headquartered in Hyderabad, India and employs approximately 27,707 people. With a market capitalization of $753 billion, AUROPHARMA is one of the largest publicly traded companies.
AUROPHARMA trades on the Indian stock exchanges (NSE/BSE) and is classified as a mega-cap-cap stock with a market capitalization of approximately $753 billion. The company employs approximately 27,707 people worldwide.
Key Statistics
- Current Price
- ₹1,296.50
- Market Cap
- ₹753.01B
- 52-Week High
- ₹1,319.80
- 52-Week Low
- ₹1,010.00
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
AUROPHARMA Investment Performance
AUROPHARMA has gained 9.6% year-to-date in 2026. Over the past 5 years, a $1,000 investment in AUROPHARMA would have grown to $1,398, representing a 39.8% total return. Since its IPO in 1996, a $1,000 investment would now be worth $305,271.
₹1,000 Invested in Aurobindo Pharma Limited (AUROPHARMA)
How much would ₹1,000 invested in AUROPHARMA be worth today?
What would ₹1,000 invested in AUROPHARMA 1 year ago be worth today?
A ₹1,000 investment in Aurobindo Pharma Limited (AUROPHARMA) in 2025 would be worth ₹1,168 as of May 2026, representing a +16.8% total return.
What would ₹1,000 invested in AUROPHARMA 3 years ago be worth today?
A ₹1,000 investment in Aurobindo Pharma Limited (AUROPHARMA) in 2023 would be worth ₹2,762 as of May 2026, representing a +176.2% total return.
What would ₹1,000 invested in AUROPHARMA 5 years ago be worth today?
A ₹1,000 investment in Aurobindo Pharma Limited (AUROPHARMA) in 2021 would be worth ₹1,398 as of May 2026, representing a +39.8% total return.
What would ₹1,000 invested in AUROPHARMA 10 years ago be worth today?
A ₹1,000 investment in Aurobindo Pharma Limited (AUROPHARMA) in 2016 would be worth ₹1,561 as of May 2026, representing a +56.1% total return.
What would ₹1,000 invested in AUROPHARMA at IPO be worth today?
A ₹1,000 investment in Aurobindo Pharma Limited (AUROPHARMA) at IPO would be worth ₹305,271 as of May 2026, representing a +30427.1% total return.
Monthly Returns Heatmap
Over the past 30+ years (362 months), Aurobindo Pharma Limited (AUROPHARMA) has averaged a monthly return of +2.97% with a median return of +1.36%. The stock had 200 positive months (55%) and 161 negative months (44%). The best month in AUROPHARMA's history was December 1999 with a +108.4% return, while the worst was October 2008 at -54.7%. Historically, December tends to be the strongest month (averaging +11.2%), and October the weakest (-2.9%).
AUROPHARMA's longest winning streak was 8 consecutive months of gains, while its longest losing streak was 6 consecutive months of losses. The best full year was 1999 with a cumulative return of +257.3%, and the worst was 2011 at -95.3%.
Annual Returns
Over 30 years of trading history, Aurobindo Pharma Limited (AUROPHARMA) has delivered an average annual return of +65.32% with a median return of +16.44%. The compound annual growth rate (CAGR) is +22.76%. The stock posted gains in 18 years (60%) and losses in 12 years (40%).
AUROPHARMA's best year was 1999 with a +574.62% gain, while the worst was 2008 at -68.64%. The longest streak of consecutive positive years was 4, and the longest losing streak was 3 years. AUROPHARMA achieved double-digit gains (10%+) in 15 years. It suffered double-digit losses in 11 years.
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | +9.59% | ₹1,183.00 | ₹1,296.50 |
| 2025 | -11.02% | ₹1,329.51 | ₹1,183.00 |
| 2024 | +23.29% | ₹1,078.39 | ₹1,329.51 |
| 2023 | +149.62% | ₹432.02 | ₹1,078.39 |
| 2022 | -39.67% | ₹716.06 | ₹432.02 |
| 2021 | -19.81% | ₹892.96 | ₹716.06 |
| 2020 | +102.95% | ₹439.99 | ₹892.96 |
| 2019 | -37.39% | ₹702.73 | ₹439.99 |
| 2018 | +6.89% | ₹657.42 | ₹702.73 |
| 2017 | +3.22% | ₹636.91 | ₹657.42 |
| 2016 | -23.31% | ₹830.50 | ₹636.91 |
| 2015 | +54.86% | ₹536.28 | ₹830.50 |
| 2014 | +190.43% | ₹184.65 | ₹536.28 |
| 2013 | +110.05% | ₹87.91 | ₹184.65 |
| 2012 | +124.65% | ₹39.13 | ₹87.91 |
| 2011 | -67.41% | ₹120.07 | ₹39.13 |
| 2010 | +46.54% | ₹81.94 | ₹120.07 |
| 2009 | +454.08% | ₹14.79 | ₹81.94 |
| 2008 | -68.64% | ₹47.17 | ₹14.79 |
| 2007 | -22.78% | ₹61.08 | ₹47.17 |
| 2006 | +72.31% | ₹35.45 | ₹61.08 |
| 2005 | +25.87% | ₹28.16 | ₹35.45 |
| 2004 | -23.53% | ₹36.83 | ₹28.16 |
| 2003 | +313.68% | ₹8.90 | ₹36.83 |
| 2002 | -7.29% | ₹9.60 | ₹8.90 |
| 2001 | -53.32% | ₹20.57 | ₹9.60 |
| 2000 | -59.59% | ₹50.90 | ₹20.57 |
| 1999 | +574.62% | ₹7.55 | ₹50.90 |
| 1998 | +68.51% | ₹4.48 | ₹7.55 |
| 1997 | +62.09% | ₹2.76 | ₹4.48 |
AUROPHARMA Investment Analysis: Valuation, Risk & Dividends
Key factors to consider when evaluating Aurobindo Pharma Limited as an investment
Valuation
AUROPHARMA currently trades at a trailing P/E ratio of 21.6, which is considered moderate relative to the broader market. The forward P/E of 17.3 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 2.1. The price-to-sales ratio is 2.3.
Dividends
Aurobindo Pharma Limited pays a dividend to shareholders with a current yield of 0.31%. This translates to $4.00 per share annually. The payout ratio of 7% indicates sustainable dividend coverage.
Risk & Volatility
AUROPHARMA has a beta of 0.06, indicating it is less volatile than the overall market. The stock's 52-week range is $1010.00 to $1319.80, and it currently trades near its 52-week high.
Analyst Ratings
Based on 27 analyst opinions, AUROPHARMA has a consensus "buy" rating. The average price target of $1345.19 suggests 3.8% upside from current levels.
Frequently Asked Questions: AUROPHARMA
What sector is AUROPHARMA in? ▼
AUROPHARMA operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. This sector includes pharmaceutical companies, biotechnology firms, medical device manufacturers, and healthcare providers.
How has AUROPHARMA performed historically? ▼
Over 30 years of trading history, AUROPHARMA has posted gains in 18 years (60% of the time). The best year was 1999 with a +574.6% return. Past performance does not guarantee future results.
How can I invest in AUROPHARMA? ▼
You can invest in AUROPHARMA through any brokerage account that offers access to Indian exchanges. Popular options include commission-free brokers like Fidelity, Charles Schwab, or Robinhood (US), or international brokers like Interactive Brokers. You can buy individual shares or invest through ETFs that hold AUROPHARMA.
Does AUROPHARMA pay dividends? ▼
Aurobindo Pharma Limited pays a dividend to shareholders with a current yield of 0.31%. This translates to $4.00 per share annually. The payout ratio of 7% indicates sustainable dividend coverage.
What does Aurobindo Pharma Limited do? ▼
Aurobindo Pharma Limited is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in Hyderabad, India.
What sector is AUROPHARMA in? ▼
AUROPHARMA operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
When did AUROPHARMA go public? ▼
Aurobindo Pharma Limited went public in 1996, making it a 30-year-old public company as of 2026.
How much would $1,000 invested in AUROPHARMA 5 years ago be worth today? ▼
A $1,000 investment in AUROPHARMA five years ago would be worth approximately $1,398 today, representing a 39.8% return.
Does AUROPHARMA pay dividends? ▼
Yes, Aurobindo Pharma Limited pays a dividend with a current yield of 0.31%, which is $4.0 per share annually.
What is AUROPHARMA's market cap? ▼
Aurobindo Pharma Limited has a market capitalization of $753 billion, classifying it as a mega-cap company.
What is AUROPHARMA's P/E ratio? ▼
AUROPHARMA has a trailing P/E ratio of 21.6 and a forward P/E of 17.3, which measures how much investors are paying per dollar of earnings.
Is AUROPHARMA a buy, hold, or sell? ▼
Based on 27 opinions, AUROPHARMA has a consensus "buy" rating. The average price target is $1345.19.
Last updated: 3/14/2026